Results 71 to 80 of about 32,871 (300)

Advanced Experiment Design Strategies for Drug Development

Advanced Intelligent Discovery, EarlyView.
Wang et al. analyze 592 drug development studies published between 2020 and 2024 that applied design of experiments methodologies. The review surveys both classical and emerging approaches—including Bayesian optimization and active learning—and identifies a critical gap between advanced experimental strategies and their practical adoption in ...
Fanjin Wang, Anthony Harker, Mohan Edirisinghe, Maryam Parhizkar   +3 more
wiley   +1 more source

Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations

International Journal of General Medicine, 2020
Anteneh Belayneh,1 Ebisa Tadese,2 Fantahun Molla2 1Department of Pharmacy, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia; 2Department of Pharmaceutics, School of Pharmacy, College of Health Sciences, Mekelle University ...
Belayneh A, Tadese E, Molla F
doaj  

Albendazole Solid Dispersions: Influence of Dissolution Medium Composition on In Vitro Drug Release [PDF]

, 2014
The rate-limiting step to drug absorption is often dissolution from the dosage form, especially for poorly soluble com-pounds. Two possibilities for improving the dissolution of these drugs are to increase the available surface area and to im-prove their
Allemandi, Daniel Alberto, Castro, Silvina Gabriela, González Vidal, Noelia Luján, Palma, Santiago Daniel, Sanchez Bruni, Sergio Fabian   +4 more
core   +1 more source

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol, Joseph K. Han, Tanya M. Laidlaw, Claire Hopkins, Anju T. Peters, Oliver Pfaar, Martin Desrosiers, Stella E. Lee, Andrew P. Lane, Claudia Chen, Yun Chon, Sandhia S. Ponnarambil, Andrew Foster, Andrew W. Lindsley, Christopher S. Ambrose   +14 more
wiley   +1 more source

Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome

Pharmaceutics
The discovery of new drugs offers valuable alternatives, particularly for treating diseases that are resistant to existing therapies or involving complex, multi-organ conditions such as metabolic syndrome. Although treatment algorithms are generally well
Wiktoria Górecka, Daria Berezovska, Monika Mrozińska, Grażyna Nowicka, Monika E. Czerwińska   +4 more
doaj   +1 more source

A comprehensive proteome and phosphoproteome atlas across nine organs of the Chinese hamster

Animal Models and Experimental Medicine, EarlyView.
This study presents the first comprehensive proteome and phosphoproteome atlas of the Chinese hamster across nine organs (heart, liver, lung, kidney, spleen, cerebral cortex, skeletal muscle, stomach, and testis or ovary). A total of 14 219 proteins were identified in the proteome, with 11 828 phosphorylated proteins and 47 122 phosphorylation sites ...
Luyao Zhang, Tao Ding, Wanjun Peng, Jie Kong, Xiaoyue Tang, Jiyu Xu, Qiaochu Wang, Zhiyi Zhang, Chunmei Shi, Yizhuo Tian, Huilan Yang, Yehong Yang, Yue Wu, Xiaoyan Liu, Jiangfeng Liu, Juntao Yang   +15 more
wiley   +1 more source

Correlations of mRNA Levels among Efflux Transporters, Transcriptional Regulators, and Scaffold Proteins in Non-Small-Cell Lung Cancer

Canadian Journal of Infectious Diseases and Medical Microbiology, 2021
Multidrug resistance (MDR) due to enhanced drug efflux activity of tumor cells can severely impact the efficacy of antitumor therapies. We recently showed that increased activity of the efflux transporter P-glycoprotein (P-gp) associated with activation ...
Xieyi Zhang, Wangyang Liu, Kazue Edaki, Yuta Nakazawa, Hiroki Kamioka, Atsushi Fujita, Ryoichi Onozato, Misa Iijima, Shigeru Tsuchida, Takahiro Arai, Yukiyoshi Fujita, Kenta Mizoi, Takuo Ogihara   +12 more
doaj   +1 more source

A theoretical framework for estimation of AUCs in complete and incomplete sampling designs. [PDF]

, 2009
Nonclinical in vivo animal studies have to be completed before starting clinical studies of the pharmacokinetic behavior of a drug in humans. The drug exposure in animal studies is often measured by the area under the concentration versus time curve (AUC)
Jaki, Thomas, Wolfsegger, Martin J.
core   +1 more source

Liposomal Delivery of L‐2‐Hydroxyglutarate for Targeting Epigenetic Dysregulation in Osteoarthritis

Advanced NanoBiomed Research, EarlyView.
Osteoarthritis involves cartilage degeneration, inflammation, and epigenetic dysregulation. A liposomal formulation of the TET1 inhibitor L‐2‐hydroxyglutarate to overcome rapid joint clearance was developed. The formulation showed good physicochemical properties, reduced inflammatory and catabolic gene expression in chondrocytes, and alleviated ...
Denise Murgia, Akshay Pandey, Raffaele Spanò, Bianca Martins Estevão, Roberto Palomba, Greta Avancini, Tamaghna Gupta, Ana Maria Lopez Estevez, Stuart B. Goodman, Nidhi Bhutani, Paolo Decuzzi   +10 more
wiley   +1 more source

Client-server multi-task learning from distributed datasets

, 2010
A client-server architecture to simultaneously solve multiple learning tasks from distributed datasets is described. In such architecture, each client is associated with an individual learning task and the associated dataset of examples.
De Nicolao, Giuseppe, Dinuzzo, Francesco, Pillonetto, Gianluigi   +2 more
core   +1 more source